IMDs of domestic pharmaceutical companies that challenge Champix (Varenicline Tartrate, Pfizer) are attracting attention.

This is because film-type formulations with enhanced convenience and SR formulations are promoting commercialization. Although generic products have already been released, demand for IMDs is expected to remain high. According to the industry on the 19th, CTC Bio, Boryung, etc. are challenging Champix as a new formulation of smoking cessation treatment.

CTC Bio applied for permission for a film-type formulation of Varenicline, the same active ingredient as Champix, for the first time in Korea in September last year. This product has a salicylate salt that is different